Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study
PURPOSEMarginal zone lymphomas (MZLs) are indolent non-Hodgkin lymphomas, categorized into three subtypes: extranodal, splenic, and nodal MZL (NMZL). MZL epidemiology and outcomes in Latin America remain underexplored.MATERIALS AND METHODSThis retrospective cohort study included patients with MZL in...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2025-04-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO-24-00495 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761061586075648 |
|---|---|
| author | Juan F. Combariza-Vallejo Rocío Orduz-Rodriguez Natalia Gomez-Lopera Claudia C. Colmenares-Mejia Monica S. Benavides-Rojas Yesica M. Calderon-Ortega Marcela Godoy-Corredor Mario Arturo Isaza-Ruget |
| author_facet | Juan F. Combariza-Vallejo Rocío Orduz-Rodriguez Natalia Gomez-Lopera Claudia C. Colmenares-Mejia Monica S. Benavides-Rojas Yesica M. Calderon-Ortega Marcela Godoy-Corredor Mario Arturo Isaza-Ruget |
| author_sort | Juan F. Combariza-Vallejo |
| collection | DOAJ |
| description | PURPOSEMarginal zone lymphomas (MZLs) are indolent non-Hodgkin lymphomas, categorized into three subtypes: extranodal, splenic, and nodal MZL (NMZL). MZL epidemiology and outcomes in Latin America remain underexplored.MATERIALS AND METHODSThis retrospective cohort study included patients with MZL in Colombia from 2000 to 2023. Patients were followed for at least 24 months from diagnosis. The primary outcomes were real-world overall survival (Rw-OS) and real-world progression-free survival (Rw-PFS).RESULTSThe cohort included 103 patients (63.1% female, 36.9% male) with a median age of 61.8 years. MALT lymphoma was the most common subtype (61.1%), followed by splenic MZL (26.2%) and NMZL (12.7%). The 60-month Rw-OS was 86.4%, and the Rw-PFS was 77.2%.CONCLUSIONMZL in Colombian patients exhibits varied clinical presentations and survival outcomes. This study underscores the importance of early detection and subtype-specific management of MZL. |
| format | Article |
| id | doaj-art-bca81442b955439eb5ff3114a66d1b73 |
| institution | DOAJ |
| issn | 2687-8941 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj-art-bca81442b955439eb5ff3114a66d1b732025-08-20T03:06:09ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412025-04-011110.1200/GO-24-00495Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective StudyJuan F. Combariza-Vallejo0Rocío Orduz-Rodriguez1Natalia Gomez-Lopera2Claudia C. Colmenares-Mejia3Monica S. Benavides-Rojas4Yesica M. Calderon-Ortega5Marcela Godoy-Corredor6Mario Arturo Isaza-Ruget7Servicio de Hematología, Clinica Universitaria Colombia, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, ColombiaLaboratorio Clínico y de Patología, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, ColombiaLaboratorio Clínico y de Patología, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, ColombiaUnidad de investigación, Fundación Universitaria Sanitas, Grupo de investigación INPAC, Bogotá, ColombiaLaboratorio Clínico y de Patología, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, ColombiaLaboratorio Clínico y de Patología, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, ColombiaLaboratorio Clínico y de Patología, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, ColombiaLaboratorio Clínico y de Patología, Clinica Colsanitas S.A., Grupo Keralty, Bogotá, ColombiaPURPOSEMarginal zone lymphomas (MZLs) are indolent non-Hodgkin lymphomas, categorized into three subtypes: extranodal, splenic, and nodal MZL (NMZL). MZL epidemiology and outcomes in Latin America remain underexplored.MATERIALS AND METHODSThis retrospective cohort study included patients with MZL in Colombia from 2000 to 2023. Patients were followed for at least 24 months from diagnosis. The primary outcomes were real-world overall survival (Rw-OS) and real-world progression-free survival (Rw-PFS).RESULTSThe cohort included 103 patients (63.1% female, 36.9% male) with a median age of 61.8 years. MALT lymphoma was the most common subtype (61.1%), followed by splenic MZL (26.2%) and NMZL (12.7%). The 60-month Rw-OS was 86.4%, and the Rw-PFS was 77.2%.CONCLUSIONMZL in Colombian patients exhibits varied clinical presentations and survival outcomes. This study underscores the importance of early detection and subtype-specific management of MZL.https://ascopubs.org/doi/10.1200/GO-24-00495 |
| spellingShingle | Juan F. Combariza-Vallejo Rocío Orduz-Rodriguez Natalia Gomez-Lopera Claudia C. Colmenares-Mejia Monica S. Benavides-Rojas Yesica M. Calderon-Ortega Marcela Godoy-Corredor Mario Arturo Isaza-Ruget Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study JCO Global Oncology |
| title | Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study |
| title_full | Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study |
| title_fullStr | Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study |
| title_full_unstemmed | Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study |
| title_short | Epidemiology and Survival of Marginal Zone Lymphoma in Colombian Patients: An Observational Retrospective Study |
| title_sort | epidemiology and survival of marginal zone lymphoma in colombian patients an observational retrospective study |
| url | https://ascopubs.org/doi/10.1200/GO-24-00495 |
| work_keys_str_mv | AT juanfcombarizavallejo epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy AT rocioorduzrodriguez epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy AT nataliagomezlopera epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy AT claudiaccolmenaresmejia epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy AT monicasbenavidesrojas epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy AT yesicamcalderonortega epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy AT marcelagodoycorredor epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy AT marioarturoisazaruget epidemiologyandsurvivalofmarginalzonelymphomaincolombianpatientsanobservationalretrospectivestudy |